Form 4: Phibro Animal Health CEO Reports Stock Transactions

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC reported sales of Class A Common Stock and conversion of Class B to Class A shares.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported changes in beneficial ownership.
• BFI Co., LLC sold 6,689 shares of Class A Common Stock on February 3, 2026, at a weighted average price of $41.2508 per share.
• BFI Co., LLC sold an additional 2,971 shares of Class A Common Stock on February 3, 2026, at a weighted average price of $41.9667 per share.
• On February 4, 2026, BFI Co., LLC converted 30,000 shares of Class B Common Stock into Class A Common Stock at an exercise price of $0.
• Following the conversion, BFI Co., LLC sold 3,520 shares of Class A Common Stock on February 4, 2026, at a weighted average price of $41.1544 per share.
• All reported sales by BFI Co., LLC were executed pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025.
• After these transactions, BFI Co., LLC indirectly holds 48,800 shares of Class A Common Stock and 19,881,034 shares of Class B Common Stock (convertible to Class A).
• Jack Bendheim directly holds 16,840 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be perceived negatively, the transactions were pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling.

Positives

• The execution of sales under a Rule 10b5-1 plan demonstrates a structured approach to managing personal liquidity, reducing the perception of opportunistic trading.
• The conversion of Class B Common Stock to Class A Common Stock increases the float of publicly tradable shares.

Negatives

• Sales by a CEO and 10% owner, even if pre-planned, can sometimes be interpreted by the market as a lack of confidence, though the 10b5-1 plan mitigates this.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which is solely for reporting insider transactions.

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a Rule 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's view of future company performance. However, the pre-planned nature typically mitigates concerns about opportunistic trading.

Related Party Transactions

• The reported transactions involve Jack Bendheim, President and CEO, Director, and 10% owner of Phibro Animal Health Corp, and BFI Co., LLC, over which Mr. Bendheim exercises voting and dispositive power. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders may observe the insider selling, but the context of a Rule 10b5-1 plan generally lessens negative interpretations regarding the company's immediate prospects.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-established Rule 10b5-1 trading plan, which indicates a planned liquidity event rather than a reaction to new material information. While insider selling can sometimes be a bearish signal, the pre-planned nature mitigates immediate concerns about the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment thesis.

Keywords

SEC Form 4, Insider Trading, Beneficial Ownership, PHIBRO ANIMAL HEALTH CORP, PAHC, Jack Bendheim, Stock Sale, Rule 10b5-1, Class A Common Stock, Class B Common Stock